Rocket Pharmaceuticals, Inc. Warrant
RCKTW
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0.17% less ownership
Funds ownership: 2.12% [Q1] → 1.95% (-0.17%) [Q2]
15% less funds holding
Funds holding: 13 [Q1] → 11 (-2) [Q2]
54% less capital invested
Capital invested by funds: $349K [Q1] → $159K (-$189K) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 4
Financial journalist opinion
We haven’t received any recent news articles for RCKTW